

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/744,846	05/24/2001		Jacques-Pierre Moreau	00537-182002	5083
;	7590	05/27/2003			
Brian R Morrill Biomeasure Incorporated 27 Maple Street				EXAMINER	
			·	BORIN, MICHAEL L	CHAEL L
Milford, MA 01757				ART UNIT	PAPER NUMBER
				1631	12
				DATE MAILED: 05/27/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/744,846

Applicant(s)

00//44,

Moreau

Office Action Summary

Examiner Michael Borin

Art Unit 1631

	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address				
	for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE $\_$ $3$ $\_$ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.						
	ions of time may be eveilable under the provisions of 37 CFR 1.136 (a). In a date of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the				
- If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. he application to become ABANDONED (35 U.S.C. § 133).				
Status						
1) 💢	Responsive to communication(s) filed on Mar 27, 2	2003				
2a) 💢	This action is <b>FINAL</b> . 2b) ☐ This act	tion is non-final.				
3) 🗆	Since this application is in condition for allowance eclosed in accordance with the practice under Ex particles.	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.				
Disposi	tion of Claims					
4) 💢	Claim(s) 5	is/are pending in the application.				
4	la) Of the above, claim(s)	is/are withdrawn from consideration.				
5) 🗆	Claim(s)	is/are allowed.				
6) 💢	Claim(s) 5	is/are rejected.				
7) 🗆	Claim(s)	is/are objected to.				
8) 🗆	Claims	are subject to restriction and/or election requirement.				
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)□	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.				
	Applicant may not request that any objection to the d	Irawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examine				
	If approved, corrected drawings are required in reply t	to this Office action.				
12)	The oath or declaration is objected to by the Exami	iner.				
Priority	under 35 U.S.C. §§ 119 and 120					
13)□	Acknowledgement is made of a claim for foreign pr	riority under 35 U.S.C. § 119(a)-(d) or (f).				
a) [	☐ All b)☐ Some* c)☐ None of:					
	1. $\square$ Certified copies of the priority documents hav	e been received.				
	2. $\square$ Certified copies of the priority documents hav	e been received in Application No				
	3. Copies of the certified copies of the priority de application from the International Bures	au (PCT Rule 17.2(a)).				
_	ee the attached detailed Office action for a list of the	·				
14) 📙	Acknowledgement is made of a claim for domestic	•				
a,∟ 15)□	The translation of the foreign language provisional Acknowledgement is made of a claim for domestic					
Attachm		priority under 35 0.5.C. 33 120 and/or 121.				
	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:						

Page 2

Art Unit: 1631

Part III DETAILED ACTION

Status of the claims

Response filed 03/27/2003 is acknowledged. Claim 5 is pending.

Claim 5 remain rejected under 35 U.S.C. 102(b) as anticipated by Coy et al (US 4,853,371) or Bogden (US 5,411,943). The rejection is maintained for the reasons of

record.

Applicant argues that the references do not teach compositions comprising

active ingredient in the amounts sufficient to treat delineated diseases or conditions.

Effective amount for treatment the laundry list of conditions, ranging from sclerosis

to cancer to panic attacks, is not identified in the claims. Specification mentions

generic dosage range of 250  $\mu$ g/kg/day to 5.0 mg/kg/day (p. 6) which, again, is not

demonstrated to be effective in treatment of any of particular disorders. Teaching of

dosages in the cited prior art is fully within the range recited in the instant

specification (see Coy, col. 4, lines 34, 35; Bogden col. 7, lines 5,6), and there is no

reason to believe that the amounts recited in the references will be completely

ineffective in treatment of the disorders mentioned in the instant claims. Since the

Office does not have the facilities for examining and comparing applicants'

Serial Number: 09/744846 Page 3

Art Unit: 1631

composition with the compositions of the prior art, the burden is on applicant to show differences between the claimed product and the products of the prior art (i.e., that the amount of the active ingredients in the compositions of the prior art is not effective in treatment of the disorders mentioned in the instant claims). See *In re* Best, 562 F.d. 1252, 195 USPQ 430 (CCPA 1977) and *In re* Fitzgerald et al., 205 USPQ 594.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Serial Number: 09/744846 Page 4

Art Unit: 1631

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Borin whose telephone number is (703) 305-4506. Dr. Borin can normally be reached between the hours of 8:30 A.M. to 5:00 P.M. EST Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on (703) 308-4028. The fax telephone number for this group is (703) 305-3014.

Any inquiry of a general nature or relating the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

May 23, 2003

MIGHAEL BORIN, PH.D. PRIMARY EXAMINER

Mars

mlb